Mechanistic description
Nanobodies conjugated to curvature-sensitive cell-penetrating peptides that preferentially penetrate highly curved or deformed membranes could achieve selective entry into tau-containing vesicles.
Evidence for (5)
MAPT mutations, tauopathy, and mechanisms of neurodegeneration.
Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.
ELAVL4, splicing, and glutamatergic dysfunction precede neuron loss in MAPT mutation cerebral organoids.
The six brain-specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes.